Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GZ 389988

Drug Profile

GZ 389988

Alternative Names: GZ 389988A; GZ389988

Latest Information Update: 12 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi; Sanofi Genzyme
  • Class Antirheumatics; Small molecules
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteoarthritis

Most Recent Events

  • 31 Dec 2018 Discontinued - Phase-II for Osteoarthritis (In the elderly, In adults) in Germany (Intra-articular) before December 2018 (Sanofi pipeline, February 2019)
  • 31 Dec 2018 Discontinued - Preclinical for Osteoarthritis in USA (Intra-articular) before December 2018 (Sanofi pipeline, February 2019)
  • 31 Jul 2018 Sanofi announces its intention to submit regulatory application for Osteoarthritis in 2022
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top